initial public offerings (IPOs) trading on American exchanges

Friday, June 26, 2015

Seres Therapeutics (MCRB) began trading on the NASDAQ on 26 June 2015

No Profit, No Sales, No Prob
  • Seres is developing a class of biological drugs to treat metabolic, inflammatory and infectious diseases. Among its leading candidates is SER-109, a treatment for large-intestine inflammation.
  • As is typical of biotech companies that come public, Seres has no revenue or profit. Also typical, investors are betting that its therapies under development will produce blockbuster sales.

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. It's SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.


215 First Street, Suite 440
United States

No comments:

Post a Comment